Have a personal or library account? Click to login
A Modern Approach to Combating HPV: Integrating Molecular Diagnostics, Population-Based Prevention, and Vaccination Strategies Cover

A Modern Approach to Combating HPV: Integrating Molecular Diagnostics, Population-Based Prevention, and Vaccination Strategies

Open Access
|Dec 2025

References

  1. Abe H, Kawahara A, Akiba J, Yamaguchi R. Advances in diagnostic liquid-based cytology. Cytopathology. 2024 Jun; 35(6):682–694. https://doi.org/10.1111/CYT.13405
  2. Abou Chacra L, Fenollar F, Diop K. Bacterial Vaginosis: What Do We Currently Know? Frontiers in Cellular and Infection Microbiology. 2022 Nov; 11:672429. https://doi.org/10.3389/fcimb.2021.672429
  3. Abreu ALP, Souza RP, Gimenes F, Consolaro MEL. A review of methods for detect human Papillomavirus infection. Virology Journal. 2012 Sep; 9(1):262. https://doi.org/10.1186/1743-422X-9-262
  4. Aden D, Zaheer S, Khan S, Jairajpuri ZS, Jetley S. Navigating the landscape of HPV-associated cancers: From epidemiology to prevention. Pathology - Research and Practice. 2024 Aug; 263:155574. https://doi.org/10.1016/J.PRP.2024.155574
  5. Akbari E, Milani A, Seyedinkhorasani M, Bolhassani A. HPV co-infections with other pathogens in cancer development: A comprehensive review. Journal of Medical Virology. 2023 Nov; 95(11). https://doi.org/10.1002/JMV.29236
  6. Alrajjal A, Pansare V, Choudhury MSR, Khan MYA, Shidham VB. Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of Uterine Cervix and Bethesda System. Cyto-Journal. 2021 Jul; 18:16. https://doi.org/10.25259/CYTOJOURNAL_24_2021
  7. Ardhaoui M, Ennaifer E, De Matos Salim AC, Gomez FM, Laasili T, Boubaker MS, Guizani I. Nested PCR followed by NGS: Validation and application for HPV genotyping of Tunisian cervical samples. PLOS ONE. 2021 Aug; 16(8):e0255914. https://doi.org/10.1371/journal.pone.0255914
  8. Audisio RA, Icardi G, Isidori AM, Liverani CA, Lombardi A, Mariani L, Mennini FS, Mitchell DA, Peracino A, Pecorelli S, Rezza G, Signorelli C, Rosati GV, Zuccotti GV. Public health value of universal HPV vaccination. Critical Reviews in Oncology/Hematology. 2016 Jan; 97:157–167. https://doi.org/10.1016/J.CRITREVONC.2015.07.015
  9. Banerjee D, Mittal S, Mandal R, Basu P. Screening technologies for cervical cancer: Overview. Cyto Journal. 2022 Mar; 19:23. https://doi.org/10.25259/CMAS_03_04_2021
  10. Bansal G, Narta K, Teltumbade MR. NextGeneration Sequencing: Technology, Advancements, and Applications. Bioinformatics: Sequences, Structures, Phylogeny (chapter). 2018; pp. 15–46.
  11. Bartosik M, Moranova L, Izadi N, Strmiskova J, Sebuyoya R, Holcakova J, Hrstka R. Advanced technologies towards improved HPV diagnostics. Journal of Medical Virology. 2024 Jan; 96(2):e29409. https://doi.org/10.1002/JMV.29409
  12. Bhatla N, Singhal S. Primary HPV screening for cervical cancer. Best Practice & Research Clinical Obstetrics & Gynaecology. 2020 May; 65:98–108. https://doi.org/10.1016/J.BPOBGYN.2020.02.008
  13. Bogusiak K, Kobos J. The role of human papillomavirus infection in the head and neck region and methods for its detection. Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists. 2014 May; 65(1):1–14. https://doi.org/10.5114/PJP.2014.42662
  14. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, & Wittet S. Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine. 2013 Nov; 31(Suppl 8):I1–I31. https://doi.org/10.1016/j.vaccine.2013.07.026
  15. Bowden SJ, Doulgeraki T, Bouras E, Markozannes G, Athanasiou A, GroutSmith H, Kechagias KS, Ellis LB, Zuber V, ChadeauHyam M, Flanagan JM, Tsilidis KK, Kalliala I, Kyrgiou M. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and followup Mendelian randomisation studies. BMC Medicine. 2023 Jul; 21(1):274. https://doi.org/10.1186/s12916-023-02965-w
  16. Bruni L, Albero G, Serrano B, Mena M, Collado J, Gómez D, Muñoz J, Bosch F, de Sanjosé S. Human Papillomavirus and Related Diseases Report WORLD. 2023. www.hpvcentre.net
  17. Burd EM. Human Papillomavirus Laboratory Testing: the Changing Paradigm. Clinical Microbiology Reviews. 2016 Apr; 29(2):291–319. https://doi.org/10.1128/CMR.00013-15
  18. Chan WS, Chan TL, Au CH, Leung CP, To MY, Ng MK, Leung SM, Chan MKM, Ma ESK, Tang BSF. An economical Nanopore sequencing assay for human papillomavirus (HPV) genotyping. Diagnostic Pathology. 2020 Dec; 15(1):1–18. https://doi.org/10.1186/s13000-020-00964-6
  19. Chen AA, Heideman DAM, Boon D, Gheit T, Snijders PJF, Tommasino M, Franceschi S, Clifford GM. Human Papillomavirus 45 Genetic Variation and Cervical Cancer Risk Worldwide. Journal of Virology. 2014 Apr; 88(8):4514–4521. https://doi.org/10.1128/JVI.03534-13
  20. Coudray MS, Madhivanan P. Bacterial vaginosis — A brief synopsis of the literature. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2020 Feb; 245:143–148. https://doi.org/10.1016/j.ejogrb.2019.12.035
  21. Crothers BA. The Bethesda System 2001: update on terminology and application. Clinical Obstetrics and Gynecology. 2005 Mar; 48(1):98–107. https://doi.org/10.1097/01.GRF.0000151572.99437.A5
  22. De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. The Lancet Oncology. 2012 Jun; 13(6):607–615. https://doi.org/10.1016/S1470-2045(12)70137-7
  23. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer. 2017 Jul; 141(4):664–670. https://doi.org/10.1002/ijc.30716
  24. de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Practice & Research Clinical Obstetrics & Gynaecology. 2018 Aug; 47:2–13. https://doi.org/10.1016/j.bpobgyn.2017.08.015
  25. Derbie A, Mekonnen D, Woldeamanuel Y, Van Ostade X, Abebe T. HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review. Infectious Agents and Cancer. 2020 Feb; 15(1):9. https://doi.org/10.1186/S13027-020-0278-X
  26. Ebrahimi F, Rasizadeh R, Sharaflou S, Aghbash PS, Shamekh A, Jafari-Sales A, Bannazadeh Baghi H. Coinfection of EBV with other pathogens: a narrative review. Frontiers in Virology. 2024 Nov; 4:1482329. https://doi.org/10.3389/fviro.2024.1482329
  27. EC Europa. Cervarix - charakterystyka produktu. 2025. https://ec.europa.eu/health/documents/community-register/2010/2010060280492/anx_80492_pl.pdf
  28. EC Europa. (2025). Gardasil 4 - charakterystyka produktu. https://ec.europa.eu/health/documents/community-register/2022/20220429155492/anx_155492_pl.pdf
  29. EU Clinical Trials Register. (2025). Clinical Trials register - Search for mRNA HPV. https://www.clinicaltrialsregister.eu/ctr-search/search?query=mRNA+HPV
  30. European Medicines Agency. (2025). Cervarix. https://www.ema.europa.eu/en/medicines/human/EPAR/cervarix
  31. European Medicines Agency. (2025a). Gardasil 4. https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil
  32. European Medicines Agency. (2025b). Gardasil 9 - charakterystyka produktu. https://www.ema.europa.eu/pl/documents/product-information/gardasil-9-epar-product-information_pl.pdf
  33. Fernandes JV, Fernandes TAA DM, de Azevedo JCV, Cobucci RNO, de Carvalho MGF, Andrade VS, De Araújo JMG. Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncology Letters. 2015 Jan; 9(3):1015–1026. https://doi.org/10.3892/OL.2015.2884
  34. Flores-Miramontes MG, Olszewski D, & Aguilar-Lemarroy A. Detection of Alpha, Beta, Gamma, and Unclassified Human Papillomaviruses in Cervical Cancer Samples From Mexican Women. Frontiers in Cellular and Infection Microbiology. 2020; 10(6):529323. https://doi.org/10.3389/fcimb.2020.00234
  35. Food and Drug Administration. (2017). Food and Drug Administration. https://www.fda.gov/media/92930/download
  36. Glinska P, Komerska K, Janik B, Olkowicz J, Jedrzejewska I, Macios A, Wieszczy P, Kaminski MF, Arbyn M, Nowakowski A. HPV testing in Polish population-based cervical cancer screening programme (HIPPO project) — study protocol of a randomised healthcare policy trial. BMC Cancer. 2023 Nov; 23(1):1118. https://doi.org/10.1186/S12885-023-11597-5
  37. Govender V, Moodley D, Naidoo M, Connoly C, Ngcapu S, Abdool Karim Q. Sexually transmitted infections in pregnancy and adverse pregnancy outcomes: A retrospective cohort study. International Journal of Gynecology & Obstetrics. 2024 Apr; 166(1):62–70. https://doi.org/10.1002/IJGO.15529
  38. gov.pl. (2025). gov.pl. https://www.gov.pl/web/zdrowie/przelom-w-profilaktyce-raka-szyjki-macicy--test-hpv-hr-i-cytologia-na-podlozu-plynnym
  39. Gradíssimo A, Burk RD. Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention. Expert Review of Molecular Diagnostics. 2017 Apr;17(4):379–391. https://doi.org/10.1080/14737159.2017.1293525
  40. Han J, Zhang L, Chen Y, Zhang Y, Wang L, Cai R, Li M, Dai Y, Dang L, Chen H, Zhu L. Global HPV vaccination programs and coverage rates: a systematic review. EClinicalMedicine. 2025 Dec;84:103290. https://doi.org/10.1016/j.eclinm.2025.103290
  41. Harper DM, DeMars LR. HPV vaccines – A review of the first decade. Gynecologic Oncology. 2017 Jan;146(1):196–204. https://doi.org/10.1016/j.ygyno.2017.04.004
  42. Hellfritsch J, Panzer M, Wagner S, Nieschke K, Grohmann M. First Results for the Evaluation of the Cervical Cancer Screening Carried Out in 2021 and 2022 in the Context of the Organized Cancer Screening Program (oKFE) Part 1 Primary Screening. Geburtshilfe Und Frauenheilkunde. 2025 Apr;85(4). https://doi.org/10.1055/A-2502-6915
  43. Jankowski M, Grudziąż-Sękowska J, Wrześniewska-Wal I, Tyszko P, Sękowski K, Ostrowski J, Gujski M, Pinkas J. National HPV Vaccination Program in Poland—Public Awareness, Sources of Knowledge, and Willingness to Vaccinate Children against HPV. Vaccines. 2023 Aug;11(8):1371. https://doi.org/10.3390/vaccines11081371
  44. Karamanou M, Agapitos E, Kousoulis A, Androutsos G. From the humble wart to HPV: a fascinating story throughout centuries. Oncology Reviews. 2010 Aug;4(3):133–135. https://doi.org/10.1007/S12156-010-0060-1
  45. Kelly H, Benavente Y, Pavon MA, De Sanjose S, Mayaud P, Lorincz AT. Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis. British Journal of Cancer. 2019 Oct;121(11):954–965. https://doi.org/10.1038/s41416-019-0593-4
  46. Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, Jin T. Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Frontiers in Public Health. 2021 Jan;8:552028. https://doi.org/10.3389/fpubh.2020.552028
  47. Koss LG, Durfee GR. Unusual Patterns Of Squamous Epithelium Of The Uterine Cervix: Cytologic And Pathologic Study Of Koilocytotic Atypia. Annals of the New York Academy of Sciences. 1956 Mar;63(6):1245–1261. https://doi.org/10.1111/J.1749-6632.1956.TB32134.X
  48. Kyrgiou M, Moscicki AB. Vaginal microbiome and cervical cancer. Seminars in Cancer Biology. 2022 Nov;86:189–198. https://doi.org/10.1016/J.SEMCANCER.2022.03.005
  49. Liu L, Li Y, Li S, Hu N, He Y, Pong R, Lin D, Lu L, Law M. Comparison of nextgeneration sequencing systems. Journal of Biomedicine & Biotechnology. 2012 Jul;2012:251364. https://doi.org/10.1155/2012/251364
  50. Magdziarz IbrahimElNur J, Ledwoch J, Łosiowska A, Biesiada A, MastalerzMigas A, NitschOsuch A, IbrahimElNur MJ, Polska strategia szczepień przeciwko NO A. Polska strategia szczepień przeciwko HPV na tle innych krajów. Medycyna Ogólna i Nauki o Zdrowiu. 2025 Jan;31(1):1–5. https://doi.org/10.26444/MONZ/199757
  51. Markowitz LE, Schiller JT. Human Papillomavirus Vaccines. The Journal of Infectious Diseases. 2021 Sep;224(12 Suppl 2):S367–S378. https://doi.org/10.1093/INFDIS/JIAA621
  52. Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Molecular Therapy. 2019 Apr;27(4):757–772. https://doi.org/10.1016/j.ymthe.2019.01.020
  53. Mateos-Lindemann ML, Pérez-Castro S, Rodríguez-Iglesias M, Pérez-Gracia MT. Diagnóstico microbiológico de la infección por virus del papiloma humano. Enfermedades Infecciosas y Microbiología Clínica. 2017 Sep;35(9):593–602. https://doi.org/10.1016/J.EIMC.2016.05.008
  54. McBride AA. Human papillomaviruses: diversity, infection and host interactions. Nature Reviews Microbiology. 2021 Sep;20(2):95–108. https://doi.org/10.1038/s41579-021-00617-5
  55. Ministerstwo Zdrowia. Szczepienia przeciw HPV - Ministerstwo Zdrowia - Portal Gov.pl. https://www.gov.pl/web/zdrowie/hpv2024.
  56. Mo Y, Ma J, Zhang H, Shen J, Chen J, Hong J, Xu Y, Qian C. Prophylactic and Therapeutic HPV Vaccines Current Scenario and Perspectives. Frontiers in Cellular and Infection Microbiology. 2022 Jul;12:909223. https://doi.org/10.3389/fcimb.2022.909223
  57. Movahed F, Darzi S, Mahdavi P, Salih Mahdi M, Qutaiba B Allela O, Naji Sameer H, Adil M, Zarkhah H, Yasamineh S, Gholizadeh O. The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV). Virology Journal. 2024 May;21(1):1–20. https://doi.org/10.1186/S12985-024-02397-9
  58. Muntinga CLP, de Vos van Steenwijk PJ, Bekkers RLM, van Esch EMG. Importance of the Immune Microenvironment in the Spontaneous Regression of Cervical Squamous Intraepithelial Lesions cSIL and Implications for Immunotherapy. Journal of Clinical Medicine. 2022 Mar;11(5):1432. https://doi.org/10.3390/jcm11051432
  59. Narodowy Fundusz Zdrowia. Narodowy Fundusz Zdrowia. 2025 Jun; dostępne online: https://www.nfz.gov.pl/aktualnosci/aktualnosci-centrali/komunikat-dla-swiadczeniodawcow,8749.html
  60. Nayar R, Wilbur DC. The Bethesda System for reporting cervical cytology Definitions criteria and explanatory notes. The Bethesda System for Reporting Cervical Cytology. 2015;1–321. https://doi.org/10.1007/978-3-319-11074-5
  61. Nayar R, Wilbur DC. The Bethesda System for Reporting Cervical Cytology: A Historical Perspective. Acta Cytologica. 2017 Jul;61(4–5):359–372. https://doi.org/10.1159/000477556
  62. Nerlander L, Champezou L, & Mardh O. Sharp increase in gonorrhoea notifications among young people EU/EEA July 2022 to June 2023. Eurosurveillance. 2024 Mar;29(10):2400113. https://doi.org/10.2807/1560-7917.ES.2024.29.10.2400113
  63. Norenhag J, Du J, Olovsson M, Verstraelen H, Engstrand L, Brusselaers N. The vaginal microbiota, human papillomavirus and cervical dysplasia a systematic review and network metaanalysis. BJOG: An International Journal of Obstetrics and Gynaecology. 2020 Jan;127(2):171–180. https://doi.org/10.1111/1471-0528.15854
  64. Nowakowski A, Cybulski M, Śliwczyński A, Chil A, Teter Z, Seroczyński P, Arbyn M, Anttila A. The implementation of an organised cervical screening programme in Poland an analysis of the adherence to European guidelines. BMC Cancer. 2015 Apr;15(1):279. https://doi.org/10.1186/S12885-015-1242-9
  65. Pacjent.gov.pl. pacjent.gov.pl. 2025 Jan; dostępne online: https://pacjent.gov.pl/aktualnosc/cytologia-czy-o-niej-pamietasz
  66. PapillomaVirus Episteme. PaVE. 2025 Jan; dostępne online: https://pave.niaid.nih.gov/locus_viewer?seq_id=HPV18REF
  67. Payne S. Family Papillomaviridae. Viruses. 2023 Jun;327–333. https://doi.org/10.1016/B978-0-323-90385-1.00031-5
  68. Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of Human Papillomavirus Vaccines An Updated Review. Drug Safety. 2017 Apr;41(4):329–346. https://doi.org/10.1007/S40264-017-0625-Z
  69. Poljak M, Oštrbenk Valenčak A, Gimpelj Domjanič G, Xu L, Arbyn M. Commercially available molecular tests for human papillomaviruses a global overview. Clinical Microbiology and Infection. 2020 Apr;26(9):1144–1150. https://doi.org/10.1016/j.cmi.2020.03.033
  70. Purandare CN. Cervical Cancer Elimination 90:70:90 Together We Can. The Journal of Obstetrics and Gynecology of India. 2024 Aug;74(4):292–294. https://doi.org/10.1007/S13224-024-02052-X
  71. Rajaram S, Gupta B. Screening for cervical cancer Choices & dilemmas. The Indian Journal of Medical Research. 2021 Aug;154(2):210–220. https://doi.org/10.4103/IJMR.IJMR_857_20
  72. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SSK, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, Forney LJ. Vaginal microbiome of reproductiveage women. Proceedings of the National Academy of Sciences of the United States of America. 2011 Mar;108(Suppl 1):4680–4687. https://doi.org/10.1073/PNAS.1002611107
  73. Ronco G, Dillner J, Elfström KM, & Naucler P. Efficacy of HPVbased screening for prevention of invasive cervical cancer followup of four European randomised controlled trials. Lancet (London, England). 2014 Feb;383(9916):524–532. https://doi.org/10.1016/S0140-6736(13)62218-7
  74. Salazar KL, Duhon DJ, Olsen R, Thrall M. A review of the FDAapproved molecular testing platforms for human papillomavirus. Journal of the American Society of Cytopathology. 2019 Sep;8(5):284–292. https://doi.org/10.1016/J.JASC.2019.06.001
  75. Schellekens HCJ, Schmidt LMS, Morré SA, van Esch EMG, de Vos van Steenwijk PJ. Vaginal Microbiota and Local Immunity in HPVInduced HighGrade Cervical Dysplasia A Narrative Review. International Journal of Molecular Sciences. 2025 Apr;26(9):3954. https://doi.org/10.3390/IJMS26093954
  76. ShenGunther J, Xia Q, Cai H, Wang Y. Cervicovaginal Microbiome and HPV A Standardized Approach to 16S/ITS NGS and Microbial Community Profiling for Viral Association. International Journal of Molecular Sciences. 2025 Aug;26(16):8090. https://doi.org/10.3390/IJMS26168090
  77. Silva DC, Gonçalves AK, Cobucci RN, Mendonça RC, Lima PH, Cavalcanti G. Immunohistochemical expression of p16, Ki67 and p53 in cervical lesions A systematic review. Pathology Research and Practice. 2017 Mar;213(7):723–729. https://doi.org/10.1016/J.PRP.2017.03.003
  78. Sitarz K, Szostek S. Food and drug administration approved molecular methods for detecting human papillomavirus infection. Ginekologia Polska. 2019 Mar;90(2):104–108. https://doi.org/10.5603/GP.2019.0018
  79. SrokaOleksiak A, Gosiewski T, Pabian W, Gurgul A, Kapusta P, LudwigSłomczyńska AH, Wołkow PP, BrzychczyWłoch M. NextGeneration Sequencing as a Tool to Detect Vaginal Microbiota Disturbances during Pregnancy. Microorganisms. 2020 Nov;8(11):1813. https://doi.org/10.3390/MICROORGANISMS8111813
  80. Su ZY, Siak PY, Leong CO, Cheah SC. The role of Epstein–Barr virus in nasopharyngeal carcinoma. Frontiers in Microbiology. 2023 Feb;14:1116143. https://doi.org/10.3389/fmicb.2023.1116143
  81. Swase TD, Fasogbon IV, Eseoghene IJ, Etukudo EM, Mbina SA, Joan C, Dangana RS, Anyanwu C, Vandu CD, Agbaje AB, Shinkafi TS, Abubarkar IB, Aja PM. The impact of HPV/HIV coinfection on immunosuppression, HPV genotype, and cervical cancer biomarkers. BMC Cancer. 2025 Feb;25(1):202. https://doi.org/10.1186/S12885-025-13516-2
  82. Tachedjian G, Aldunate M, Bradshaw CS, Cone RA. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Research in Microbiology. 2017 Sep;168(9–10):782–792. https://doi.org/10.1016/j.resmic.2017.04.001
  83. Tamarelle J, Thiébaut ACM, de Barbeyrac B, Bébéar C, Ravel J, DelarocqueAstagneau E. The vaginal microbiota and its association with human papillomavirus Chlamydia trachomatis Neisseria gonorrhoeae and Mycoplasma genitalium infections a systematic review and metaanalysis. Clinical Microbiology and Infection. 2019 Jan;25(1):35–47. https://doi.org/10.1016/j.cmi.2018.04.019
  84. Tuna M, Amos CI. Next generation sequencing and its applications in HPVassociated cancers. Oncotarget. 2016 Oct; 8(5):8877–8889. https://doi.org/10.18632/ONCOTARGET.12830
  85. Vojtechova Z, Tachezy R. Genome integration of human DNA oncoviruses. Journal of Virology. 2025 Jul; 99(8). https://doi.org/10.1128/jvi.00562-25
  86. Waheed D e N, Schiller J, Stanley M, Franco EL, Poljak M, Kjaer SK, del Pino M, van der Klis F, Schim van der Loeff MF, Baay M, Van Damme P, Vorsters A. Human papillomavirus vaccination in adults impact opportunities and challenges – a meeting report. BMC Proceedings. 2021 Jul; 15(7):1–15. https://doi.org/10.1186/S12919-021-00217-4
  87. Whitaker NJ, Glenn WK, Sahrudin A, Orde MM, Delprado W, Lawson JS. Human papillomavirus and Epstein Barr virus in prostate cancer Koilocytes indicate potential oncogenic influences of human papillomavirus in prostate cancer. Prostate. 2013 Jul; 73(3):236–241. https://doi.org/10.1002/PROS.22562
  88. Williams J, Kostiuk M, Biron VL. Molecular Detection Methods in HPVRelated Cancers. Frontiers in Oncology. 2022 Apr; 12:864820. https://doi.org/10.3389/fonc.2022.864820
  89. Wolf J, Kist LF, Pereira SB, Quessada MA, Petek H, Pille A, Maccari JG, Mutlaq MP, Nasi LA. Human papillomavirus infection Epidemiology biology host interactions cancer development prevention and therapeutics. Reviews in Medical Virology. 2024 Mar;34(3):e2537. https://doi.org/10.1002/RMV.2537
  90. World Health Organization. World Health Organization. 2021. https://iris.who.int/server/api/core/bitstreams/329a5f3d-b423-48b3-beb1-26ee1240c0a3/content
  91. Wu H, Li L, Fu K, Shen YF, Lu Y, Liao Z, Liu Y, Zha W, Wu L, Zhang Y. Effects of different valent vaccines against human papillomavirus HPV to prevent persistent HPV16/18 infections and CIN2+ in women a systematic review and network meta analysis. International Journal of Infectious Diseases. 2025 Jan; 151:107363. https://doi.org/10.1016/j.ijid.2024.107363
  92. Ye H, Song T, Zeng X, Li L, Hou M, Xi M. Association between genital mycoplasmas infection and human papillomavirus infection abnormal cervical cytopathology and cervical cancer a systematic review and meta analysis. Archives of Gynecology and Obstetrics. 2018 Jun;297(6):1377–1387. https://doi.org/10.1007/S00404-018-4733-5
  93. Yousefi Z, Aria H, Ghaedrahmati F, Bakhtiari T, Azizi M, Bastan R, Hosseini R, Eskandari N. An Update on Human Papilloma Virus Vaccines History Types Protection and Efficacy. Frontiers in Immunology. 2022 Jan;12. https://doi.org/10.3389/FIMMU.2021.805695
  94. Zeng M, Li X, Jiao X, Cai X, Yao F, Xu S, Huang X, Zhang Q, Chen J. Roles of vaginal flora in human papillomavirus infection virus persistence and clearance. Frontiers in Cellular and Infection Microbiology. 2023 Jan;12:1036869. https://doi.org/10.3389/FCIMB.2022.1036869
  95. Zhang J, Ke Y, Chen C, Jiang Z, Liu H, Liu Y, Cao H. HPV cancer burden by anatomical site country and region in 2022. Scientific Reports. 2025 Jan;15(1):1–11. https://doi.org/10.1038/s41598-025-06700-8
DOI: https://doi.org/10.2478/am-2025-0022 | Journal eISSN: 2545-3149 | Journal ISSN: 0079-4252
Language: English, Polish
Page range: 278 - 299
Submitted on: Nov 26, 2025
|
Accepted on: Dec 15, 2025
|
Published on: Dec 31, 2025
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Katarzyna Biegun-Drożdż, Sława Szostek, Monika Brzychczy-Włoch, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.